“There is a principle which is a bar against all information, which is proof against all arguments, and which cannot fail to keep a person in everlasting ignorance — that principle is contempt prior to investigation.”

-Paley and Poole

Andrew Howard, PhD


Dr. Andrew Howard is an industry professional drug hunter with a lifetime of experience in identifying and validating unique biological mechanisms. Dr. Howard spent over two decades at the Merck Research Laboratories responsible for Discovery research in the areas of endocrinology (hypothalamic-pituitary adrenal axis), gastrointestinal, neuroscience, and most recently Type II diabetes and obesity. Dr. Howard is an expert in all phases of early drug development from novel target identification and validation, biomarker and target engagement discovery and validation, lead compound identification, preclinical candidate selection, and shepherding of molecules in clinical development though Phase 1. Following his work at Merck, Dr. Howard joined the CHDI Foundation as a Scientific Director, and subsequently established an Early Drug Discovery Consulting LLC to provide expertise on all phases of the early discovery process. Dr. Howard has Co-authored ~100 peer-reviewed scientific articles as well as 62 patents (16 issued) and ~12 regulatory documents (IND, CTA, IB).

Dr. Howard received his B.S from Fairleigh Dickinson University, a Ph.D. in molecular characterization of opioid receptors from the Department of Pharmacology, New York University School of Medicine, and studied the trafficking and synthesis of membrane proteins in laboratory of Dr. Sidney Udenfriend at the Roche Institute of Molecular Biology as a Post-Doctoral Fellow.